WHY IT MATTERS: Pregnant patients who have used cannabis, even early in pregnancy, may want to discuss this emerging research with their obstetric and psychiatric care teams when considering their child’s long-term neurodevelopmental monitoring. CLINICAL OVERVIEW: Emerging research suggests that prenatal cannabis exposure may produce measurable epigenetic and gene expression changes in placental tissue, particularly in pathways associated with neurodevelopmental risk including schizophrenia. The placenta, long underappreciated as a window into fetal programming, appears to reflect cannabis-related disruptions that could correlate with altered brain development trajectories in offspring.
Do anything, become nothing – The Morning News
WHY IT MATTERS: If you are a parent, caregiver, or young adult considering cannabis, this study reinforces that adolescent brain development is a critical window where unsupervised use may carry serious long-term psychiatric risks that do not necessarily apply to adult medical patients under clinical guidance. CLINICAL OVERVIEW: A new longitudinal study links adolescent cannabis use to increased risk of later bipolar and psychotic disorder diagnoses, adding to a growing body of evidence that the developing brain is uniquely vulnerable to cannabinoid exposure. While this research does not apply directly to adult medical cannabis patients, it reinforces what clinicians in cannabis medicine have long emphasized: age of onset matters enormously, and adolescent use carries a fundamentally different risk profile than supervised adult medical use.